| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Gustav Paumgartner | |
| P2860 | cites work | OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia | Q24297458 |
| Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis | Q28139039 | ||
| Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver | Q28143360 | ||
| MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis | Q28213568 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11 | Q28276140 | ||
| Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production | Q28379482 | ||
| Bile salt-induced apoptosis involves NADPH oxidase isoform activation | Q28574660 | ||
| Enterohepatic bile salt transporters in normal physiology and liver disease | Q28609705 | ||
| The human bile salt export pump: characterization of substrate specificity and identification of inhibitors | Q28612066 | ||
| Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers | Q32075349 | ||
| Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis | Q32171369 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Inflammation-induced cholestasis | Q33756581 | ||
| Hepatobiliary transport | Q33870213 | ||
| Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited | Q34146325 | ||
| Bile salt transporters: molecular characterization, function, and regulation | Q34186800 | ||
| Death receptor-mediated apoptosis and the liver | Q34783540 | ||
| Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease | Q35734498 | ||
| Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis | Q36066753 | ||
| Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? | Q36219960 | ||
| Mechanisms and regulation of bile secretion | Q37253872 | ||
| A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation | Q37383640 | ||
| Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice | Q38343998 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Characterization of the mouse bile salt export pump overexpressed in the baculovirus system | Q40807260 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease | Q42545724 | ||
| Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study | Q42551010 | ||
| The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions | Q43579874 | ||
| Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver | Q43601206 | ||
| Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver | Q43662715 | ||
| Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats | Q43697146 | ||
| A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis | Q43770466 | ||
| Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment | Q43878341 | ||
| Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression | Q44324978 | ||
| Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis | Q44487597 | ||
| Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis | Q44499429 | ||
| Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane | Q44527593 | ||
| Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice | Q44569549 | ||
| Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine | Q44583396 | ||
| Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. | Q44805394 | ||
| Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. | Q44825209 | ||
| Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice | Q44965243 | ||
| Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid | Q45022689 | ||
| The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis | Q45134599 | ||
| Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. | Q45175716 | ||
| No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis | Q45279435 | ||
| Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial | Q45309693 | ||
| Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis | Q46446538 | ||
| Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans | Q46637413 | ||
| Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver | Q46848216 | ||
| Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome | Q46852534 | ||
| 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice | Q46939923 | ||
| Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo | Q47869512 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. | Q54017726 | ||
| Molecular pathogenesis of cholestasis. | Q54344101 | ||
| Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | Q70670255 | ||
| Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis | Q70824652 | ||
| Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment | Q70871974 | ||
| Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis | Q71173367 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis | Q73107770 | ||
| Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study | Q73167014 | ||
| Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up | Q73317238 | ||
| Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes | Q73486365 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis | Q73979498 | ||
| Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat | Q77308908 | ||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 4445-4451 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets | |
| P478 | volume | 12 |
| Q46207889 | Absence of glycochenodeoxycholic acid (GCDCA) in human bile is an indication of cholestasis: a 1H MRS study |
| Q33908105 | Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction |
| Q34108895 | Biliary physiology and disease: reflections of a physician-scientist |
| Q46823993 | CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury |
| Q91867502 | Dietary Bile Acids Enhance Growth, and Alleviate Hepatic Fibrosis Induced by a High Starch Diet via AKT/FOXO1 and cAMP/AMPK/SREBP1 Pathway in Micropterus salmoides |
| Q43166399 | Effect of rosuvastatin on cholestasis-induced hepatic injury in rat livers |
| Q92886852 | Emerging roles of bile acids in mucosal immunity and inflammation |
| Q44950247 | Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway |
| Q37287597 | Intestinal bile acid physiology and pathophysiology. |
| Q30487320 | Liver progenitor cells fold up a cell monolayer into a double-layered structure during tubular morphogenesis |
| Q37254347 | Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? |
| Q35741546 | New perspectives for the treatment of cholestasis: lessons from basic science applied clinically |
| Q43005234 | Pharmacotherapy of cholestatic liver diseases |
| Q46459855 | Protection of human colon epithelial cells against deoxycholate by rottlerin |
| Q47121237 | Protective effect of dehydroandrographolide on obstructive cholestasis in bile duct-ligated mice |
| Q46641706 | Superiority of ceftriaxon to cefazolin in a rat model of obstructive jaundice: an experimental study. |
| Q37254611 | Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses |
| Q33643380 | Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling |
Search more.